A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of
trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with
HER2-positive Metastatic Breast Cancer